Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFRvIII/CD3 bispecific antibody hEGFRvIII:CD3 bi-scFv

A bispecific antibody and T-cell engager composed of two single chain variable fragments (bi-scFvs) directed against both a mutant form of the human epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), and the epsilon subunit of the human T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFRvIII/CD3 bispecific antibody hEGFRvIII:CD3 bi-scFv specifically binds to both CD3 on cytotoxic T lymphocytes (CTLs) and hEGFRvIII on hEGFRvIII-expressing tumor cells. This crosslinks T cells and tumor cells, and activates and redirects CTLs to hEGFRvIII-expressing tumor cells. This leads to CTL-mediated killing of hEGFRvIII-expressing tumor cells. hEGFRvIII, a mutant form of EGFR expressed in certain tumor cell types and frequently seen in malignant glioma, plays a key role in tumor cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BRiTE
hEGFRvIII-CD3-bi-scFv bispecific T-cell engager
hEGFRvIII:CD3 bi-scFv
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search